|17th November 2020||Daniel N Jr Swisher||10,000||Open or private sale||$6.25||$62,505.00|
|17th November 2020||Daniel N Jr Swisher||10,000||Exercise of derivative||$2.90||$29,000.00|
|19th October 2020||Daniel N Jr Swisher||5,000||Exercise of derivative||$6.55||$32,750.00|
|19th October 2020||Daniel N Jr Swisher||5,000||Open or private sale||$17.66||$88,301.00|
|13th October 2020||Eric Bjerkholt||23,905||Sale back to the issuer||$34.50||$824,722.50|
|10th October 2020||Eric Bjerkholt||27,805||Disposition due to a tender of shares in a change of control transaction||$34.50||$959,272.50|
|5th October 2020||Eric Bjerkholt||4,281||Exercise of derivative||$0.00|
|5th October 2020||Eric Bjerkholt||5,200||Exercise of derivative||$19.44||$101,088.00|
|15th September 2020||Eric Bjerkholt||840||Payment by withholding||$34.25||$28,770.00|
|5th September 2020||Timothy L. Moore||4,296||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The company produces blood system for platelets and plasma. It markets products under the INTERCEPT brand.